Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the activity and tolerability of pazopanib in subjects with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy exists and to characterize the pharmacokinetics of pazopanib in this subject population.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00297258
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 2
Start date	November 2005
Completion date	February 2014

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03985722` - Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients	Phase 1
Withdrawn	`NCT02464332` - Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery	Phase 1
Completed	`NCT00289809` - TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients	Phase 1/Phase 2
Completed	`NCT00243685` - Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis	Phase 2/Phase 3
Active, not recruiting	`NCT01185964` - A Study of IMC-3G3 in Soft Tissue Sarcoma	Phase 1/Phase 2
Completed	`NCT00753688` - Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy	Phase 3
Completed	`NCT00187174` - Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors	Phase 1
Completed	`NCT00093080` - Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)	Phase 2
Completed	`NCT03798795` - Radiomics for Tumor Grading of Soft Tissue Sarcomas.
Terminated	`NCT02929394` - Trabectedin Maintenance Post 1st-line in STS	Phase 3
Recruiting	`NCT02275286` - Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients	Phase 1/Phase 2
Completed	`NCT00406601` - BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas	Phase 2
Active, not recruiting	`NCT06114173` - Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma	Early Phase 1
Completed	`NCT00061659` - Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma	Phase 2
Recruiting	`NCT03815474` - Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients	Phase 2
Recruiting	`NCT02812654` - Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment	Phase 2
Completed	`NCT00204620` - Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)	Phase 2
Completed	`NCT03058406` - A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas
Active, not recruiting	`NCT02415816` - Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas	N/A
Withdrawn	`NCT02367651` - Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma	Phase 2